Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 473
Filter
1.
Rev Assoc Med Bras (1992) ; 70(4): e20231359, 2024.
Article in English | MEDLINE | ID: mdl-38716945

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the relationship between uterine leiomyoma and fragmented QRS, a non-invasive indicator of cardiovascular risk and myocardial ischemia, in women with uterine leiomyoma. METHODS: In this prospective case-control study, a total of 47 patients diagnosed with uterine leiomyoma (case group) and 47 healthy individuals without uterine leiomyoma (control group) who had undergone bilateral tubal ligation surgery were included. Various demographic, clinical, and laboratory parameters and the presence of fragmented QRS were recorded. RESULTS: The leiomyoma group showed significantly higher body mass index (27.46±2.18 vs. 25.9±2.87 kg/m2, p=0.005) and waist circumference (91.34±9.30 vs. 84.97±9.3 cm, p=0.001) compared with the control group. Uterine volumes were also significantly higher in the leiomyoma group (235.75±323.48 vs. 53.24±12.81 mm3, p<0.001). The presence of fragmented QRS was detected in 18.1% of the patients. Multiple regression analysis identified age, fasting blood glucose value, and the presence of fragmented QRS as independent risk factors for the presence of leiomyoma. CONCLUSION: This study provides valuable insights into the relationship between uterine leiomyoma and fragmented QRS. The presence of fragmented QRS was identified as an independent risk factor for the presence of leiomyoma. Further research is needed to better understand the underlying mechanisms connecting uterine leiomyoma and cardiovascular health.


Subject(s)
Electrocardiography , Leiomyoma , Uterine Neoplasms , Humans , Female , Leiomyoma/physiopathology , Leiomyoma/complications , Prospective Studies , Case-Control Studies , Adult , Uterine Neoplasms/physiopathology , Uterine Neoplasms/complications , Middle Aged , Body Mass Index , Risk Factors , Myocardial Ischemia/physiopathology
2.
Respirar (Ciudad Autón. B. Aires) ; 16(1): 17-21, Marzo 2024.
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1551135

ABSTRACT

Introducción: Los leiomiomas uterinos son un tipo de neoplasia benigna de frecuente aparición en mujeres de edad reproductiva, relacionados con enfermedad tromboem- bólica venosa. Este vínculo surge del efecto producido por la compresión de fibromas que genera estasis venosa en la región pelviana. Sin embargo, este pareciera no ser el único factor que lo relaciona con el desarrollo posterior de hipertensión pulmonar, sino que su presencia es gatillo de una serie de fenómenos que influyen sobre la vasculatu - ra pulmonar y también a nivel sistémico. Método: Revisión de una serie de casos (seis) atendidos en nuestra unidad, seguido de una revisión sobre la relación entre leiomio- mas y distintas formas de hipertensión pulmonar con una revisión desde la fisiopatología. Resultado y conclusiones: Encontramos sustento bibliográfico en los múltiples caminos fisiopatológicos que relacionan los mediadores vasculares comunes, que parecieran ser el punto clave en la relación entre estas dos patologías.


Introduction: Uterine leiomyomas are a type of benign neoplasm that frequently appears in women of reproductive age, related to venous thromboembolic disease. This link arises from the effect produced by the compression of fibroids, which generates venous stasis in the pelvic region. However, this seems not to be the only factor that re- lates it to the subsequent development of pulmonary hypertension, but rather its presence is a trigger for a series of phenomena that influence the pulmonary vasculature and also at a systemic level. Method: Review of a series of cases (six) cared for in our unit, followed by a review on the relationship between leiomyomas and different forms of pulmonary hypertension with a review from the pathophysiology. Result and conclusions: We found bibliographic support in the multiple pathophysiological paths that relate the common vascular mediators, which appear to be the key point in the relationship between these two pathologies.


Subject(s)
Humans , Female , Adult , Middle Aged , Uterine Neoplasms/physiopathology , Venous Thromboembolism/physiopathology , Hypertension, Pulmonary/physiopathology , Leiomyoma/physiopathology , Echocardiography , Cardiac Catheterization/methods , Biomarkers , Review , Computed Tomography Angiography/methods
3.
Am J Obstet Gynecol ; 225(4): 403.e1-403.e22, 2021 10.
Article in English | MEDLINE | ID: mdl-34058169

ABSTRACT

BACKGROUND: Uterine artery embolization is an effective and safe technique for the treatment of uterine fibroids, but its use remains controversial for women who wish to procreate. OBJECTIVE: This study aimed to study the clinical, anatomic, and obstetrical results of uterine artery embolization in patients of childbearing age not eligible for myomectomy. STUDY DESIGN: This was a retrospective cohort study of 398 female patients under the age of 43 years who were treated by uterine artery embolization between 2003 and 2017 for symptomatic fibroids and/or adenomyosis. Uterine artery embolization was performed according to a standardized procedure (fertility-sparing uterine artery embolization technique), with ovarian protection in the event of dangerous utero-ovarian anastomosis. Magnetic resonance imaging and pelvic ultrasounds were performed before and after uterine artery embolization. RESULTS: The overall clinical success rate (ie, resolution of preembolization symptoms such as heavy menstrual bleeding, iron-deficiency anemia, pelvic pressure) was 91.2%, and there were no major complications. One year after uterine artery embolization, we observed a mean 73% reduction in myoma volume. A total of 108 patients (49.3%) presented with dangerous utero-ovarian anastomosis and 33 (14.5%) benefited from ovarian protection. In our group, there were 148 pregnancies and 109 live births; 74 children were born at term; 23 were born preterm, on average at 35.12±2.78 weeks. Including preterm births, the mean birthweight and birth length of the children were within normal limits. Restoration of uterine anatomy and ovarian protection were identified as the main predictive factors for obstetrical success. Restoration was also a major predictive factor for clinical success and was associated with a lower rate of miscarriage. CONCLUSION: This study provided detailed clinical and obstetrical outcomes for 398 female patients who underwent uterine artery embolization for fibroid treatment; it contributes to the identification of anatomic and technical factors that could have an impact on fertility after uterine artery embolization. Further controlled clinical trials are needed to confirm our findings and reevaluate this procedure's indications and limitations for women with a desire to procreate.


Subject(s)
Abortion, Spontaneous/epidemiology , Leiomyoma/therapy , Ovary/blood supply , Pregnancy Rate , Premature Birth/epidemiology , Uterine Artery Embolization/methods , Uterine Neoplasms/therapy , Adult , Anemia, Iron-Deficiency/physiopathology , Female , Humans , Leiomyoma/physiopathology , Magnetic Resonance Imaging , Menorrhagia/physiopathology , Pelvic Pain/physiopathology , Pregnancy , Treatment Outcome , Uterine Neoplasms/physiopathology
4.
Reproduction ; 162(2): R1-R18, 2021 07 08.
Article in English | MEDLINE | ID: mdl-34034234

ABSTRACT

Fibroids are benign tumors caused by the proliferation of myometrial smooth muscle cells in the uterus that can lead to symptoms such as abdominal pain, constipation, urinary retention, and infertility. While traditionally thought of as a disease process intrinsic to the uterus, accumulating evidence suggests that fibroid growth may be linked with the systemic vasculature system, although cell-intrinsic factors are certainly of principal importance in their inception. Fibroids are associated with essential hypertension and preeclampsia, as well as atherosclerosis, for reasons that are becoming increasingly elucidated. Factors such as the renin-angiotensin-aldosterone system, estrogen, and endothelial dysfunction all likely play a role in fibroid pathogenesis. In this review, we lay out a framework for reconceptualizing fibroids as a systemic vascular disorder, and discuss how pharmaceutical agents and other interventions targeting the vasculature may aid in the novel treatment of fibroids.


Subject(s)
Leiomyoma/physiopathology , Vascular Diseases/pathology , Animals , Female , Humans , Pregnancy , Vascular Diseases/etiology
5.
Medicine (Baltimore) ; 100(3): e24306, 2021 Jan 22.
Article in English | MEDLINE | ID: mdl-33546059

ABSTRACT

BACKGROUND: Uterine leiomyoma (UL) is a common severe gynecological issue. In China, Xuefu Zhuyu Decoction (XFZYD), combined with Mifepristone, is widely used in the treatment of UL. However, their combined effectiveness and safety for this purpose have not yet been explored. OBJECTIVE: This systematic review aims to evaluate the effectiveness and safety of XFZYD combined with Mifepristone as a method of treatment for UL. METHODS: We searched the following 7 databases: 3 English medical databases (PubMed, EMBASE, Cochrane Library), and 4 Chinese medical databases (Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), and the Wanfang database). The primary outcome was the effect of XFZYD combined with Mifepristone on the effective rate, uterine leiomyoma volume (ULV), and uterine volume (UV) of uterine leiomyoma. Bias risk was assessed using the Cochrane risk of bias tool. The software RevMan5 was used to evaluate the quality of the included studies and process the data. RESULTS: This study will evaluate the efficacy and safety of XFZYD combined with Mifepristone in the treatment of uterine fibroids by evaluating the effective rate, Uterine Leiomyoma volume, and uterine volume, the incidence of estradiol, luteinizing hormone, and other indicators. CONCLUSION: This study will provide reliable evidence-based evidence for Xuefu Zhuyu Decoction Combined with Mifepristone in the treatment of uterine fibroids. ETHICS AND DISSEMINATION: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval will not be required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/YADN3.


Subject(s)
Clinical Protocols , Drugs, Chinese Herbal/therapeutic use , Leiomyoma/drug therapy , Mifepristone/therapeutic use , Drugs, Chinese Herbal/adverse effects , Hormone Antagonists/adverse effects , Hormone Antagonists/therapeutic use , Humans , Leiomyoma/physiopathology , Meta-Analysis as Topic , Mifepristone/adverse effects , Systematic Reviews as Topic
7.
J Vasc Interv Radiol ; 32(3): 332-338, 2021 03.
Article in English | MEDLINE | ID: mdl-33468366

ABSTRACT

PURPOSE: To investigate differences in outcomes of uterine artery embolization (UAE) for leiomyoma when performed during different phases of the menstrual cycle. MATERIALS AND METHODS: In this single-institution retrospective analysis, 111 premenopausal patients (median [range] age, 44 [33-52] years) undergoing UAE for symptomatic leiomyoma between June 2014 and February 2020 were included. Twenty-one patients underwent UAE in the menstrual phase (the early follicular phase), 27 in the late follicular phase, and 63 in the luteal phase. Baseline characteristics and technical and peri-procedural outcomes were compared among groups. Leiomyoma infarction on contrast-enhanced magnetic resonance imaging 1 week after UAE and 4-month outcomes, including changes in the Uterine Fibroid Symptom and Quality of Life questionnaire scores, the volume reduction rates of the uterus and largest leiomyoma, follicle stimulating hormone values, adverse events, and amenorrhea, were compared among groups. RESULTS: A 4-month follow-up was completed for all patients. No significant differences were observed among groups in baseline characteristics or technical and peri-procedural outcomes. There were no significant differences in the multivariate-adjusted 1-week infarction rates of all leiomyoma volumes (P = .161) or multivariate-adjusted 4-month outcomes, including changes in the Uterine Fibroid Symptom and Quality of Life questionnaire symptoms and total scores (P = .864 and P = .798, respectively), the volume reduction rates of the uterus and the largest leiomyoma (P = .865 and P = .965, respectively), and follicle stimulating hormone values (P = .186) among the groups. No significant differences were noted in the 4-month adverse events (P = .260) or amenorrhea (P = .793) among the groups. CONCLUSIONS: The present study demonstrated no significant differences in the outcomes of UAE for leiomyoma when performed during different phases of the menstrual cycle.


Subject(s)
Leiomyoma/therapy , Menstrual Cycle , Uterine Artery Embolization , Uterine Neoplasms/therapy , Adult , Female , Humans , Leiomyoma/diagnostic imaging , Leiomyoma/physiopathology , Middle Aged , Retrospective Studies , Treatment Outcome , Uterine Artery Embolization/adverse effects , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/physiopathology
9.
Am J Obstet Gynecol ; 223(5): 624-664, 2020 11.
Article in English | MEDLINE | ID: mdl-32707266

ABSTRACT

Women's health concerns are generally underrepresented in basic and translational research, but reproductive health in particular has been hampered by a lack of understanding of basic uterine and menstrual physiology. Menstrual health is an integral part of overall health because between menarche and menopause, most women menstruate. Yet for tens of millions of women around the world, menstruation regularly and often catastrophically disrupts their physical, mental, and social well-being. Enhancing our understanding of the underlying phenomena involved in menstruation, abnormal uterine bleeding, and other menstruation-related disorders will move us closer to the goal of personalized care. Furthermore, a deeper mechanistic understanding of menstruation-a fast, scarless healing process in healthy individuals-will likely yield insights into a myriad of other diseases involving regulation of vascular function locally and systemically. We also recognize that many women now delay pregnancy and that there is an increasing desire for fertility and uterine preservation. In September 2018, the Gynecologic Health and Disease Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development convened a 2-day meeting, "Menstruation: Science and Society" with an aim to "identify gaps and opportunities in menstruation science and to raise awareness of the need for more research in this field." Experts in fields ranging from the evolutionary role of menstruation to basic endometrial biology (including omic analysis of the endometrium, stem cells and tissue engineering of the endometrium, endometrial microbiome, and abnormal uterine bleeding and fibroids) and translational medicine (imaging and sampling modalities, patient-focused analysis of menstrual disorders including abnormal uterine bleeding, smart technologies or applications and mobile health platforms) to societal challenges in health literacy and dissemination frameworks across different economic and cultural landscapes shared current state-of-the-art and future vision, incorporating the patient voice at the launch of the meeting. Here, we provide an enhanced meeting report with extensive up-to-date (as of submission) context, capturing the spectrum from how the basic processes of menstruation commence in response to progesterone withdrawal, through the role of tissue-resident and circulating stem and progenitor cells in monthly regeneration-and current gaps in knowledge on how dysregulation leads to abnormal uterine bleeding and other menstruation-related disorders such as adenomyosis, endometriosis, and fibroids-to the clinical challenges in diagnostics, treatment, and patient and societal education. We conclude with an overview of how the global agenda concerning menstruation, and specifically menstrual health and hygiene, are gaining momentum, ranging from increasing investment in addressing menstruation-related barriers facing girls in schools in low- to middle-income countries to the more recent "menstrual equity" and "period poverty" movements spreading across high-income countries.


Subject(s)
Global Health , Health Literacy , Menstrual Hygiene Products , Menstruation , Uterine Hemorrhage , Women's Health , Adenomyosis/physiopathology , Attitude , Biological Evolution , Biomedical Research , Congresses as Topic , Developing Countries , Education , Endometriosis/physiopathology , Endometrium/cytology , Endometrium/microbiology , Endometrium/physiology , Female , Humans , Leiomyoma/physiopathology , Menstruation Disturbances/physiopathology , Mesenchymal Stem Cells , Microbiota , Microfluidic Analytical Techniques , National Institute of Child Health and Human Development (U.S.) , Regeneration/physiology , Stem Cells/physiology , Terminology as Topic , Tissue Engineering , United States , Uterine Neoplasms/physiopathology , Uterus/cytology , Uterus/diagnostic imaging , Uterus/microbiology , Uterus/physiology
10.
Am J Obstet Gynecol ; 223(5): 674-708.e8, 2020 11.
Article in English | MEDLINE | ID: mdl-32474012

ABSTRACT

OBJECTIVE: Despite the high prevalence of uterine fibroids, the psychosocial impact of fibroids has not been evaluated across different quality of life indicators and compared with other chronic conditions. Here, we rigorously analyzed available evidence pertaining to the psychosocial burden of uterine fibroids in premenopausal women and compared validated quality of life and symptom scores before and after treatment. DATA SOURCES: We searched PubMed, PsycINFO, ClinicalTrials.gov, Embase, and Cochrane Library for publications from January 1990 to January 2020. STUDY ELIGIBILITY CRITERIA: We considered English-language publications that evaluated the association between uterine fibroids diagnosed by imaging studies in premenopausal women and quality of life by standardized and validated questionnaires at baseline and after treatment. We used a detailed list of terms related to quality of life, questionnaires, and uterine fibroids to conduct the search. METHODS: Three reviewers screened titles and abstracts and then obtained full-text articles for further analysis. The reviewers assessed risk of bias using established Cochrane and Newcastle-Ottawa Scale guidelines. The quality of life scores of premenopausal women with fibroids were reviewed at baseline and compared with those of published quality of life scores in other disease populations in addition to after fibroid treatment. RESULTS: A total of 57 studies were included in the review: 18 randomized controlled trials and 39 observational studies. Of note, the 36-Item Short Form Survey and European Quality of Life Five-Dimension Scale questionnaires both indicated a diagnosis of uterine fibroids to have a disability score that was similar to or exceeded (was a greater psychosocial stressor) a diagnosis of heart disease, diabetes mellitus, or breast cancer. Quality of life scores were lower at baseline than after treatment in all instruments measuring these variables in women with uterine fibroids, indicating significantly impaired psychosocial functioning. Uterine fibroids were associated with significant patient-reported health disabilities related to bodily pain, mental health, social functioning, and satisfaction with sex life. CONCLUSION: A diagnosis of uterine fibroids was a significant psychosocial stressor among women at baseline and relative to other diseases. Validated quality of life instruments indicated therapeutic success and the improvement of both physical and emotional symptoms after treatment.


Subject(s)
Leiomyoma/psychology , Mental Health , Quality of Life , Sexual Health , Social Participation , Uterine Neoplasms/psychology , Contraceptive Agents, Hormonal/therapeutic use , Female , Gonadotropin-Releasing Hormone/agonists , Gonadotropin-Releasing Hormone/antagonists & inhibitors , Humans , Hysterectomy , Leiomyoma/physiopathology , Leiomyoma/therapy , Premenopause , Uterine Artery Embolization , Uterine Myomectomy , Uterine Neoplasms/physiopathology , Uterine Neoplasms/therapy
11.
J Assist Reprod Genet ; 37(8): 1963-1974, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32572673

ABSTRACT

PURPOSE: To evaluate the effect of non-cavity-distorting intramural leiomyomas on the placental histopathology pattern and perinatal outcome in singleton live births resulting from in vitro fertilization treatment. METHODS: The study population included all singleton live births following in vitro fertilization treatment with autologous oocytes during the period from 2009 to 2017. Primary outcomes included anatomical, inflammation, vascular malperfusion, and villous maturation placental features. Secondary outcomes included fetal, maternal, delivery, and perinatal complications. RESULTS: A total of 1119 live births were included in the final analysis and were allocated to the group of pregnancies with non-cavity-distorting intramural myomas (n = 101) and without myomas (n = 1018). After the adjustment for confounding factors, the non-cavity-distorting intramural myomas were found to be significantly associated with assisted placental delivery (OR 2.4; 95% CI 1.5-3.9), furcate cord insertion (OR 3.6; 95% CI 1.4-9.3), circumvallate membranes insertion (OR 5.2; 95% CI 1.4-19.3), chronic deciduitis (OR 8.2; 95% CI 1.6-42.2), focal intramural fibrin deposition (OR 25.1; 95% CI 2.1-306.2), subchorionic thrombi (OR 3.6; 95% CI 1.7-7.6), maternal vasculopathy (OR 2.5; 95% CI 1.2-5.5), and chorangioma (OR 5.9; 95% CI 1.4-25.2) as well as with the failure of labor progress (OR 2.4; 95% CI 1.3-4.4) and induction (OR 3.2; 95% CI 1.2-9.0). CONCLUSION: Intramural non-cavity-distorting myomas have a significant impact on the placental histopathology with a higher incidence of dysfunctional labor.


Subject(s)
Fertilization in Vitro , Inflammation/physiopathology , Leiomyoma/physiopathology , Placenta/physiopathology , Adult , Female , Humans , Infertility, Female/epidemiology , Infertility, Female/physiopathology , Inflammation/epidemiology , Leiomyoma/epidemiology , Live Birth/epidemiology , Pregnancy , Pregnancy Outcome , Pregnancy Rate
12.
Ginekol Pol ; 91(7): 373-378, 2020.
Article in English | MEDLINE | ID: mdl-32542642

ABSTRACT

OBJECTIVES: To evaluate magnetic resonance elastography as a tool for characterizing uterine leimyomas. MATERIAL AND METHODS: At total of 12 women with symptomatic leiomyomas diagnosed in physical and ultrasound examinations were enrolled in this pilot study. Before surgery, all patients underwent magnetic resonance elastography of the uterus using a 1.5 T MR whole-body scanner (Optima, GE Healthcare, Milwaukee, WI, USA). Surgical specimens were forwarded for histological examination. The findings were allocated into 3 categories depending on the percentage content of connective tissue: below 15%, from 15 to 30% and more than 30%. The median stiffness of leiomyomas for each of the group was calculated. The U-Mann Whitney test was used for statistical analysis. RESULTS: The stiffness of the leiomyomas ranged between 3.7-6.9 kPa (median value 4.9 kPa). The concentration of extracellular components in the leiomyomas did not exceed 40%. An increasing trend of the stiffness with the growing percentage of extracellular component was observed. Stiffness of the leiomyomas obtained by MRE varies depending on microscopic composition. CONCLUSIONS: The value of stiffness shows a trend of increasing with the percentage of extracellular component of the leiomyoma. Further studies are required to assess the usefulness of MRE in diagnostics of uterine leiomyomas.


Subject(s)
Leiomyoma/diagnostic imaging , Uterine Neoplasms/diagnostic imaging , Adult , Elasticity Imaging Techniques , Female , Humans , Leiomyoma/physiopathology , Leiomyoma/surgery , Magnetic Resonance Imaging , Middle Aged , Pilot Projects , Uterine Neoplasms/physiopathology , Uterine Neoplasms/surgery , Young Adult
13.
J Int Med Res ; 48(5): 300060520923492, 2020 May.
Article in English | MEDLINE | ID: mdl-32458705

ABSTRACT

OBJECTIVE: To investigate the associations between serum vitamin D, calcium and uterine fibroids in a Chinese female population. METHODS: In this case-control study, adult female patients with fibroids (cases) were compared with females without fibroids (controls) in terms of serum 25-hydroxyvitamin D (25OHD) and calcium levels. RESULTS: Out of 546 total participants (mean age, 41.68 ± 5.99 years; 279 with fibroids and 267 without fibroids), only 232 had serum 25OHD levels above the sufficient threshold (>20 ng/ml). In addition, females with fibroids had lower serum 25OHD levels versus those without fibroids. The prevalence of fibroids in females with deficient (<12 ng/ml) and insufficient (12-20 ng/ml) 25OHD levels were significantly higher than in females with sufficient (>20 ng/ml) 25OHD levels. Serum calcium levels were within normal range in both groups. CONCLUSION: Hypovitaminosis D was highly prevalent among a population of Chinese females of reproductive-age, and serum 25OHD levels were lower in female patients with fibroids.


Subject(s)
Calcium/analysis , Leiomyoma/metabolism , Vitamin D/analysis , Adult , Asian People , Calcifediol/analysis , Calcifediol/blood , Calcium/blood , Case-Control Studies , China/epidemiology , Female , Humans , Leiomyoma/epidemiology , Leiomyoma/physiopathology , Middle Aged , Parathyroid Hormone/blood , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D Deficiency/blood
14.
Medicine (Baltimore) ; 99(17): e19884, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32332661

ABSTRACT

To identify significant clinical and CT features for the differentiation of gastrointestinal stromal tumors (GISTs) from leiomyomas in the esophagogastric junction (EGJ).One hundred thirty six patients with pathologically proven GISTs (n = 87) and leiomyomas (n = 49) in the EGJ were enrolled. And preoperative CT images were available in 73 GISTs cases and 34 leiomyoma cases. Two radiologists reviewed the CT images by consensus with regard to tumor size, shape, growth pattern, surface, enhancement pattern, enhancement degree, attention at each phasic image and the presence of surface ulcer, calcification, and intralesional low attention.Eight significant clinical and CT features were identified for differentiating GISTs from leiomyomas: older age (>46.5 years), tumor long diameter >4.5 cm, heterogeneous enhancement, high degree enhancement, mean CT attenuation >69.2 HU, presences of intralesional low attenuation and surface ulcer, absences of calcification (P < .05). On the receiver operating characteristic curve analysis, an optimal cutoff score of 3.5 was achieved for differentiating GISTs from leiomyomas with an AUC of 0.844 (sensitivity: 76.7%, specificity: 76.5%).older age (>46.5 years), tumor long diameter >4.5 cm, heterogeneous enhancement, high degree enhancement, mean CT attenuation >69.2 HU, presences of intralesional low attenuation and surface ulcer, absence of calcification are significant features highly suggestive of GISTs in differentiation from leiomyomas in the EGJ.


Subject(s)
Gastrointestinal Stromal Tumors/etiology , Leiomyoma/complications , Adult , Aged , Analysis of Variance , China , Female , Gastrointestinal Stromal Tumors/physiopathology , Humans , Leiomyoma/physiopathology , Male , Middle Aged , ROC Curve , Tomography, X-Ray Computed/methods
15.
BMJ Open ; 10(3): e032220, 2020 03 04.
Article in English | MEDLINE | ID: mdl-32139480

ABSTRACT

INTRODUCTION: Millions of women suffer from the consequences of endometriosis and uterine fibroids, with fibroids the cause for over 50% of hysterectomies in the USA, and direct costs for their treatment estimated at between US$4 and US$9 billion. Endometriosis commonly affects millions of women worldwide predominantly during reproductive age, with severe menstrual and non-menstrual pain and subfertility the main symptoms. Due to the 'unhappy triad' of endometriosis-lack of awareness, lack of clinically relevant biomarkers and the unspecific nature of symptoms-women wait on average for 8-12 years before the definitive endometriosis diagnosis is made. Treatment options for both conditions are not satisfactory at the moment, especially with a view to preserving fertility for the women and families affected. In the Fibroids and Endometriosis Oxford (FENOX) study, we combine the investigation of fibroids and endometriosis, and plan to collect high-quality tissue samples and medical data of participants over a time frame of 5 years after surgical intervention. METHODS AND ANALYSIS: Biological samples such as blood, saliva, urine, fat, peritoneal fluid and-if found-endometrial tissue or fibroids as well as detailed clinical and intraoperative data will be collected from women undergoing surgery and participating in the study after informed consent. We plan to recruit up to 1200 participants per disease arm (ie, endometriosis and uterine fibroids) over 5 years. Participants will fill in detailed and validated questionnaires on their medical history and quality of life, with follow-ups for 5 years. Enrolment started on 2 April 2018, and FENOX will close on 31 March 2028. We will analyse the biological samples using state-of-the-art molecular biology methods and correlate the findings with the medical records and questionnaire data. ETHICS AND DISSEMINATION: The findings will be published in high-ranking journals in the field and presented at national and international conferences. TRIAL REGISTRATION NUMBER: ISRCTN13560263.


Subject(s)
Endometriosis/physiopathology , Leiomyoma/physiopathology , Quality of Life , Adult , Female , Humans , Longitudinal Studies , Prospective Studies , Research Design
16.
Gynecol Obstet Invest ; 85(2): 107-117, 2020.
Article in English | MEDLINE | ID: mdl-31968333

ABSTRACT

The junctional zone endometrium (JZE) is a compacted layer of smooth muscle cells with little extracellular matrix. The innermost myometrium adjacent to the endometrium, JZE is best visualized and evaluated on T2-weighted magnetic resonance imaging (MRI) and two-dimensional/three-dimensional transvaginal ultrasound (TVUS) scanning. Increased thickness of JZE >12 mm on MRI images has been associated with myometrial and subendometrial pathologic conditions, such as, adenomyosis, and is considered a poor prognostic factor for implantation. Gonadotrophin-releasing hormone analogue (GnRHa) has been proposed as a treatment for adenomyosis and fibroids larger than 7 cm, and overall improvement in symptoms and disease progression were attributed to JZE thinning after GnRHa treatment. JZE contractility and frequency of contractions are affected by ovarian hormone cyclic activity and pathologic changes adjacent to JZE, such as fibroids and polyps. However, JZE contractility is not evaluated by TVUS during gynecological examinations because guidelines do not exist and the process is time consuming. The present data indicate that JZE is an important part of the nongravid uterus anatomy, structure, and functionality. When more evidence is available, the morphologic features, thickness, and contractility of JZE may potentially be used as markers for diagnosis and prognosis of normal and abnormal uterine function, for early stages of pregnancy, and possibly for early detection of endometrial cancer. A new tool for JZE measurements should be further investigated to fill this clinical gap. Key Message: JZE is an important component of the nongravid uterus anatomy, structure, and functionality. The thickness and contractility of JZE could potentially be used as markers for diagnosis and prognosis of normal and abnormal uterine function, early stages of pregnancy, and early detection of endometrial cancer. A new tool for JZE measurements should be further investigated.


Subject(s)
Endometrium/pathology , Endometrium/physiopathology , Adenomyosis/diagnostic imaging , Adenomyosis/pathology , Adult , Embryo Implantation , Endometrial Neoplasms/diagnostic imaging , Endometrial Neoplasms/pathology , Endometrial Neoplasms/physiopathology , Endometrium/diagnostic imaging , Female , Humans , Leiomyoma/diagnostic imaging , Leiomyoma/pathology , Leiomyoma/physiopathology , Magnetic Resonance Imaging/methods , Myometrium/diagnostic imaging , Myometrium/pathology , Myometrium/physiopathology , Pregnancy , Ultrasonography/methods , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/pathology , Uterine Neoplasms/physiopathology , Uterus/diagnostic imaging , Uterus/pathology
17.
Gynecol Endocrinol ; 36(1): 87-92, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31328597

ABSTRACT

To evaluate quality of life and sexual function of childbearing-age women, affected by uterine fibromatosis undergoing medical treatment with ulipristal acetate. The data obtained by filling the questionnaires European Quality of Life Five-Dimension Scale and modified Female Sexual Function Index, were analyzed to assess UPA usefulness in improving QoL and sexual activity. A total of 139 patients affected by uterine fibromatosis undergoing conservative ulipristal acetate treatment were enrolled in this prospective observational cohort study. Seventy-one women (average age 46.5 years) answered the questionnaires: QoL and sexuality were evaluated before and after ulipristal acetate treatment. 59 patients (83.1%) had an improvement of QoL and general health state, with a reduction of VAS score after ulipristal acetate treatment. EQ-5D-5L showed a statistically significant improvement of usual act impairment, mobility, discomfort, anxiety/depression (p < .0005). There was no difference in personal care management after therapy. Modified FSFI showed a statistically significant improvement (p < .0001) of sexual satisfaction and sexual life. A not statistically significant improvement in dyspareunia was also highlighted. This study provides a clear picture about QoL impact on women and confirms the effectiveness of the ulipristal acetate in improving different aspects of daily and sexual life of patients undergoing medical treatment.


Subject(s)
Contraceptive Agents, Hormonal/therapeutic use , Leiomyoma/drug therapy , Neoplasms, Multiple Primary/drug therapy , Norpregnadienes/therapeutic use , Quality of Life , Sexual Health , Uterine Neoplasms/drug therapy , Activities of Daily Living , Adult , Anxiety/psychology , Depression/psychology , Dysmenorrhea/physiopathology , Dyspareunia/physiopathology , Dyspareunia/psychology , Female , Humans , Leiomyoma/physiopathology , Leiomyoma/psychology , Libido , Menorrhagia/physiopathology , Metrorrhagia/physiopathology , Middle Aged , Neoplasms, Multiple Primary/physiopathology , Neoplasms, Multiple Primary/psychology , Pelvic Pain/physiopathology , Prospective Studies , Sexual Dysfunction, Physiological/physiopathology , Treatment Outcome , Uterine Neoplasms/physiopathology , Uterine Neoplasms/psychology
18.
Eur J Contracept Reprod Health Care ; 25(1): 37-42, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31821047

ABSTRACT

Objectives: The primary purpose of the study was to investigate a possible association between uterine fibroids and time to pregnancy (TTP), and, secondly, to explore the effect of myomectomy on TTP.Methods: This historical cohort study used data from the Danish National Birth Cohort and the Danish National Patient Registry. The study population consisted of 86,323 women with 92,696 pregnancies. The main outcome was TTP; groups were compared using a binary outcome: TTP >12 months or TTP ≤12 months.Results: Women who had a fibroid diagnosis code before attempting to conceive (n = 92) had an increased risk of TTP >12 months compared with women without a fibroid diagnosis code (n = 87,358) (adjusted odds ratio [OR] 1.67; 95% confidence interval [CI] 1.05, 6.68). Women who had a fibroid diagnosis code after pregnancy (n = 963) also had an increased risk of TTP >12 months compared with women without a fibroid diagnosis code (adjusted OR 1.24; 95% CI 1.04, 1.47).Conclusion: We found an association between having a uterine fibroid diagnosis code and TTP >12 months. We were not able to make a valid assessment of the effect of myomectomy on TTP.


Subject(s)
Leiomyoma/physiopathology , Time-to-Pregnancy/physiology , Uterine Myomectomy/statistics & numerical data , Uterine Neoplasms/physiopathology , Adult , Cohort Studies , Denmark , Female , Humans , Leiomyoma/surgery , Odds Ratio , Pregnancy , Time Factors , Treatment Outcome , Uterine Neoplasms/surgery
19.
Medicina (Kaunas) ; 55(9)2019 Aug 30.
Article in English | MEDLINE | ID: mdl-31480288

ABSTRACT

Background and Objectives: Hormonal replacement therapy (HRT) is effective in treating many debilitating symptoms of menopause. However, its use in women with uterine fibroids is widely debated, based on the susceptibility of these tumors to sexual steroids. This review aims to ascertain the effects of HRT on leiomyomas development and growth in postmenopausal women. Materials and Methods: Electronic databases (i.e., MEDLINE, Scopus, ClinicalTrials.gov, EMBASE, Sciencedirect, the Cochrane Library at the CENTRAL Register of Controlled Trials, Scielo) were searched from January 1990 until May 2019. All English-written studies evaluating the impact of various HRT regimens on uterine leiomyomas were selected. Results: Seventeen papers, considering a total of 1122 participants, were included. Fifteen of these were prospective trials, of which nine were randomized controlled trials. The remaining two works were a retrospective observational trial and a retrospective case series respectively. Five studies evaluated the effects of tibolone, also comparing it with various estrogen/progestin combinations, while two were about raloxifene. Thirteen studies compared different combinations of estrogens/progestins, the most common being transdermal estrogens (used in nine studies) and medroxyprogesterone acetate at different doses (used in 10 studies). Conclusions: For women with uterine fibroids, the choice of the most appropriate HRT regimen is crucial to avoid leiomyomas growth and the symptoms possibly related to it. Available data are conflicting, but suggest that uterine fibroids might be influenced by HRT, without representing an absolute contraindication to hormonal replacement therapy. Women with uterine fibroids subjected to HRT should be periodically examined and hormonal treatment should be discontinued if leiomyomas appear to increase in size. Moreover, the minimal effective dose of progestin should be employed.


Subject(s)
Estrogen Replacement Therapy/adverse effects , Leiomyoma/physiopathology , Progestins/pharmacology , Uterine Neoplasms/physiopathology , Disease Progression , Estrogens/adverse effects , Estrogens/pharmacology , Female , Humans , Leiomyoma/diagnostic imaging , Leiomyoma/drug therapy , Postmenopause , Progestins/adverse effects , Ultrasonography , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/drug therapy , Uterus/drug effects
20.
J Obstet Gynaecol Can ; 41(10): 1521-1524, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31548041

ABSTRACT

OBJECTIVES: The aim of this guideline is to provide clinicians with an update to the 2015 Clinical Practice Guideline on the Management of Uterine Fibroids. As new information and evidence has become available since 2015, the Gynaecology Clinical Practice Committee of the Society for Obstetricians and Gynaecologists of Canada has determined that an addendum to that document was necessary to inform members about treatment modalities for uterine fibroids. OUTCOMES: Implementation of this guideline update should optimize the decision-making process of women and their health care providers in proceeding with further investigation or therapy for uterine leiomyomas, having considered the disease process and available treatment options and reviewed the risks and anticipated benefits. EVIDENCE: Published literature was retrieved through searches of PubMed, CINAHL, and Cochrane Systematic Reviews in February 2015 to April 2018, using appropriate controlled vocabulary (uterine fibroids, myoma, leiomyoma, myomectomy, myolysis, heavy menstrual bleeding, and menorrhagia) and key words (myoma, leiomyoma, fibroid, myomectomy, uterine artery embolization, hysterectomy, heavy menstrual bleeding, menorrhagia). The reference lists of articles identified were also searched for other relevant publications. Results were restricted to systematic reviews, randomized controlled trials or controlled clinical trials, and observational studies. There were no date limits, but results were limited to English or French language materials. Searches were updated on a regular basis and incorporated in the guideline to April 2018. Most of the unpublished data have not been evaluated scientifically. The product monograph was also reviewed up to December 31st, 2018. BENEFITS, HARMS, AND COSTS: The majority of fibroids are asymptomatic and require no intervention or further investigations. For symptomatic fibroids such as those causing menstrual abnormalities (e.g., heavy, irregular, and prolonged uterine bleeding), iron deficiency anemia, or bulk symptoms (e.g., pelvic pressure/pain, obstructive symptoms), hysterectomy is a definitive solution. However, it is not the preferred solution for women who wish to preserve fertility and/or their uterus. The selected treatment should be directed towards an improvement in symptomatology and quality of life. The cost of the therapy to the health care system and to women with fibroids must be interpreted in the context of the cost of untreated disease conditions and the cost of ongoing or repeat investigative or treatment modalities. VALUES: The quality of evidence in this document was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Contraceptive Agents, Hormonal/therapeutic use , Leiomyoma/drug therapy , Leuprolide/therapeutic use , Menorrhagia/drug therapy , Norpregnadienes/therapeutic use , Uterine Neoplasms/drug therapy , Anemia/drug therapy , Anemia/etiology , Female , Gonadotropin-Releasing Hormone/agonists , Hematinics/therapeutic use , Humans , Iron Compounds/therapeutic use , Leiomyoma/complications , Leiomyoma/physiopathology , Liver Function Tests , Menorrhagia/etiology , Menorrhagia/physiopathology , Uterine Neoplasms/complications , Uterine Neoplasms/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...